AR086984A1 - Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer - Google Patents
Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancerInfo
- Publication number
- AR086984A1 AR086984A1 ARP120102176A ARP120102176A AR086984A1 AR 086984 A1 AR086984 A1 AR 086984A1 AR P120102176 A ARP120102176 A AR P120102176A AR P120102176 A ARP120102176 A AR P120102176A AR 086984 A1 AR086984 A1 AR 086984A1
- Authority
- AR
- Argentina
- Prior art keywords
- cxcr4
- cancer treatment
- cxcr4 antibody
- chain variable
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente solicitud se refiere a un método para tratar el cáncer mediante la administración de un anticuerpo monoclonal anti-CXCR4 que tiene la capacidad de inducir una o más funciones efectoras.Reivindicación 1: Un anticuerpo humanizado que se une a CXCR4, o un fragmento de unión que contiene CH2 de éste; dicho anticuerpo humanizado comprende un dominio variable de la cadena pesada que se selecciona entre las secuencias SEQ ID Nº 7 a 10 y un dominio variable de la cadena ligera que se selecciona entre las secuencias SEQ ID Nº 11 a 17; para su empleo en un método del tratamiento del cáncer mediante la destrucción de una célula cancerígena que expresa CXCR4 mediante la inducción de, al menos, una función efectora, en la presencia de células efectoras o componentes del complemento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161499004P | 2011-06-20 | 2011-06-20 | |
EP11305773 | 2011-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086984A1 true AR086984A1 (es) | 2014-02-05 |
Family
ID=44718440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102176A AR086984A1 (es) | 2011-06-20 | 2012-06-19 | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140120555A1 (es) |
EP (1) | EP2721069A1 (es) |
JP (1) | JP6223966B2 (es) |
KR (1) | KR20140041698A (es) |
CN (1) | CN103649120A (es) |
AR (1) | AR086984A1 (es) |
AU (1) | AU2012274104B2 (es) |
BR (1) | BR112013032456A2 (es) |
CA (1) | CA2838484A1 (es) |
MA (1) | MA35173B1 (es) |
MX (1) | MX2013015061A (es) |
RU (1) | RU2013158624A (es) |
WO (1) | WO2012175576A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI623551B (zh) * | 2013-08-02 | 2018-05-11 | 輝瑞大藥廠 | 抗cxcr4抗體及抗體-藥物結合物 |
TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
US20180273897A1 (en) * | 2015-09-18 | 2018-09-27 | The General Hospital Corporation | Modified t-cells having anti-fugetactic properties and uses thereof |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
CN112513079A (zh) * | 2018-03-13 | 2021-03-16 | 拉巴斯大学医院生物医学研究基金会 | 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体 |
WO2019191133A1 (en) | 2018-03-27 | 2019-10-03 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
KR20220012292A (ko) | 2019-05-23 | 2022-02-03 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 배양 배지를 모니터링하는 방법 |
CN116406369A (zh) | 2020-10-05 | 2023-07-07 | 百时美施贵宝公司 | 用于浓缩蛋白质的方法 |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2568899T3 (es) * | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CN100423777C (zh) * | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
CA2616256C (en) | 2005-07-22 | 2016-10-25 | Kyowa Hakko Kogyo Co., Ltd. | Genetically modified antibody composition |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
HUE033630T2 (en) * | 2006-10-02 | 2017-12-28 | Squibb & Sons Llc | CXCR4 binding human antibodies and their use |
CN102027015A (zh) * | 2008-05-14 | 2011-04-20 | 伊莱利利公司 | 抗cxcr4抗体 |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2011
- 2011-06-20 US US14/126,944 patent/US20140120555A1/en not_active Abandoned
-
2012
- 2012-06-19 AR ARP120102176A patent/AR086984A1/es unknown
- 2012-06-20 JP JP2014516330A patent/JP6223966B2/ja not_active Expired - Fee Related
- 2012-06-20 MX MX2013015061A patent/MX2013015061A/es not_active Application Discontinuation
- 2012-06-20 BR BR112013032456A patent/BR112013032456A2/pt not_active IP Right Cessation
- 2012-06-20 CA CA2838484A patent/CA2838484A1/en not_active Abandoned
- 2012-06-20 RU RU2013158624/10A patent/RU2013158624A/ru not_active Application Discontinuation
- 2012-06-20 CN CN201280030414.8A patent/CN103649120A/zh active Pending
- 2012-06-20 WO PCT/EP2012/061893 patent/WO2012175576A1/en active Application Filing
- 2012-06-20 EP EP12729573.1A patent/EP2721069A1/en not_active Withdrawn
- 2012-06-20 AU AU2012274104A patent/AU2012274104B2/en not_active Ceased
- 2012-06-20 KR KR1020147000453A patent/KR20140041698A/ko not_active Application Discontinuation
-
2013
- 2013-12-10 MA MA36547A patent/MA35173B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140041698A (ko) | 2014-04-04 |
EP2721069A1 (en) | 2014-04-23 |
MA35173B1 (fr) | 2014-06-02 |
JP6223966B2 (ja) | 2017-11-01 |
JP2014525899A (ja) | 2014-10-02 |
AU2012274104B2 (en) | 2017-06-15 |
MX2013015061A (es) | 2014-07-30 |
CA2838484A1 (en) | 2012-12-27 |
WO2012175576A1 (en) | 2012-12-27 |
NZ618655A (en) | 2015-09-25 |
US20140120555A1 (en) | 2014-05-01 |
AU2012274104A1 (en) | 2014-01-09 |
BR112013032456A2 (pt) | 2016-11-22 |
CN103649120A (zh) | 2014-03-19 |
RU2013158624A (ru) | 2015-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086984A1 (es) | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer | |
ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
DOP2017000031A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
AR083293A1 (es) | Agentes de union a cd33 | |
ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
AR068818A1 (es) | Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |